Literature DB >> 26971872

Computing Substrate Selectivity in a Peptide Transporter.

Claire Colas1, David E Smith2, Avner Schlessinger3.   

Abstract

The human proton-coupled peptide transporter 1 (PepT1) is responsible for the absorption of di- and tri-peptides from the diet and peptide-like drugs. In this issue of Cell Chemical Biology, Samsudin et al. (2016) use an integrated computational and experimental approach to provide new insights into understanding substrate selectivity of PepTSt, a prokaryotic homolog of the human PepT1.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26971872      PMCID: PMC5457801          DOI: 10.1016/j.chembiol.2016.02.001

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  7 in total

Review 1.  The oligopeptide transporter hPepT1: gateway to the innate immune response.

Authors:  Laetitia Charrier; Didier Merlin
Journal:  Lab Invest       Date:  2006-06       Impact factor: 5.662

2.  Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET.

Authors:  Avner Schlessinger; Ethan Geier; Hao Fan; John J Irwin; Brian K Shoichet; Kathleen M Giacomini; Andrej Sali
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-01       Impact factor: 11.205

Review 3.  Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications.

Authors:  David E Smith; Benjamin Clémençon; Matthias A Hediger
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

Review 4.  A Call for Systematic Research on Solute Carriers.

Authors:  Adrián César-Razquin; Berend Snijder; Tristan Frappier-Brinton; Ruth Isserlin; Gergely Gyimesi; Xiaoyun Bai; Reinhart A Reithmeier; David Hepworth; Matthias A Hediger; Aled M Edwards; Giulio Superti-Furga
Journal:  Cell       Date:  2015-07-30       Impact factor: 41.582

5.  Alternating access mechanism in the POT family of oligopeptide transporters.

Authors:  Nicolae Solcan; Jane Kwok; Philip W Fowler; Alexander D Cameron; David Drew; So Iwata; Simon Newstead
Journal:  EMBO J       Date:  2012-06-01       Impact factor: 11.598

6.  Ligand Discovery for the Alanine-Serine-Cysteine Transporter (ASCT2, SLC1A5) from Homology Modeling and Virtual Screening.

Authors:  Claire Colas; Christof Grewer; Nicholas James Otte; Armanda Gameiro; Thomas Albers; Kurnvir Singh; Helen Shere; Massimiliano Bonomi; Jeff Holst; Avner Schlessinger
Journal:  PLoS Comput Biol       Date:  2015-10-07       Impact factor: 4.475

7.  Structural basis for polyspecificity in the POT family of proton-coupled oligopeptide transporters.

Authors:  Joseph A Lyons; Joanne L Parker; Nicolae Solcan; Alette Brinth; Dianfan Li; Syed T A Shah; Martin Caffrey; Simon Newstead
Journal:  EMBO Rep       Date:  2014-06-10       Impact factor: 8.807

  7 in total
  5 in total

Review 1.  Advances and Challenges in Rational Drug Design for SLCs.

Authors:  Rachel-Ann A Garibsingh; Avner Schlessinger
Journal:  Trends Pharmacol Sci       Date:  2019-09-10       Impact factor: 14.819

2.  Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1.

Authors:  Claire Colas; Masayuki Masuda; Kazuaki Sugio; Seiji Miyauchi; Yongjun Hu; David E Smith; Avner Schlessinger
Journal:  Mol Pharm       Date:  2017-11-15       Impact factor: 4.939

3.  SLC Transporters: Structure, Function, and Drug Discovery.

Authors:  Claire Colas; Peter Man-Un Ung; Avner Schlessinger
Journal:  Medchemcomm       Date:  2016-03-28       Impact factor: 3.597

4.  Rosetta Broker for membrane protein structure prediction: concentrative nucleoside transporter 3 and corticotropin-releasing factor receptor 1 test cases.

Authors:  Dorota Latek
Journal:  BMC Struct Biol       Date:  2017-08-03

5.  Studies of structural determinants of substrate binding in the Creatine Transporter (CreaT, SLC6A8) using molecular models.

Authors:  Claire Colas; Giulia Banci; Riccardo Martini; Gerhard F Ecker
Journal:  Sci Rep       Date:  2020-04-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.